TY - JOUR T1 - Non-alcoholic fatty liver disease JF - Clinical Medicine JO - Clin Med SP - 509 LP - 512 DO - 10.7861/clinmed.2020-0696 VL - 20 IS - 5 AU - Wenhao Li AU - William Alazawi Y1 - 2020/09/01 UR - http://www.rcpjournals.org/content/20/5/509.abstract N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD is defined by excess fat in the liver and has a multidirectional relationship with metabolic syndrome. The prevalence of NAFLD has risen rapidly in recent years in line with the obesity epidemic and associated increases in type 2 diabetes, hypertension and hypercholesterolaemia. Patients with NAFLD are at risk of cardiovascular disease and cancer, and in a proportion of individuals, NAFLD is associated with liver damage. This article summarises the epidemiology of NAFLD, the clinical approach to risk-assessing patients and briefly outlines current and future management options. ER -